Vivotif® – A ‘Magic Shield’ for Protection against Typhoid Fever and Delivery of Heterologous Antigens
| Autor: | Guido Dietrich, Joachim Fensterle, Simon A. Rothen, Andre Collioud, Werner Goebel, Fabian Mollet, Monika Griot-Wenk, Jon Pearman, Simone Spreng, Ulf R. Rapp, Jose A. Ures, Heike Sieber, Ivaylo Gentschev |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.drug_class
Ty21a Genetic Vectors Antibiotics Vaccines Attenuated Salmonella typhi complex mixtures Typhoid fever Microbiology Hemolysin Proteins Antigen Antigens Heterophile Drug Discovery Typhoid-Paratyphoid Vaccines Animals Humans Medicine Pharmacology (medical) Typhoid Fever Pharmacology business.industry Heterologous Antigens Escherichia coli Proteins Polysaccharides Bacterial General Medicine bacterial infections and mycoses medicine.disease Virology Infectious Diseases Oncology business |
| Zdroj: | Chemotherapy. 53:177-180 |
| ISSN: | 1421-9794 0009-3157 |
| Popis: | The attenuated Salmonella typhi strain Ty21a is the main constituent of Vivotif®, the only attenuated live oral vaccine against typhoid fever. In comparison with antibiotics, the ‘magic bullets’ which Paul Ehrlich was striving for to treat infectious diseases, this vaccine should be viewed as a ‘magic shield’, because rather than treating typhoid fever after the infection has started, immunisation with this vaccine strain prevents infection and disease by the induction of specific immune responses. Ty21a is also an attractive carrier for the delivery of heterologous antigens. Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|